What Peptide–MHC Multimer T Cell Analysis Covers
Peptide–MHC multimer analysis is used by research teams to detect and characterize antigen-specific T cell populations in samples of interest, typically by staining cells with fluorescently labeled peptide–MHC multimers and reading the result by flow cytometry.Our service supports projects that need peptide-loaded or peptide-ready MHC reagents prepared in a coordinated workflow, followed by multimer-based T cell analysis.Projects can be configured around Class I systems using a heavy chain, β2-microglobulin, and a target peptide, or Class II systems in a matched alpha/beta chain pair format, depending on the allele and the T cell population being studied.
Typical engagements move from an upfront feasibility review of peptide, allele, and intended assay format into custom peptide supply, monomer assembly, purification, and, where the readout requires it, biotinylation and multimer assembly with a fluorescent label.
Pairing multimer staining with antigen-specific T cell response assays helps distinguish antigen recognition from functional responsiveness.
What the Service Can Include
Custom Allele and Peptide Support
Class I and Class II projects can be configured around the alleles and peptide sequences relevant to your study, including peptide sequence review, handling recommendations for difficult sequences, and parallel peptide sets when multiple candidates need to be compared.
Monomer Preparation and Multimer Conversion
Peptide-loaded or peptide-ready MHC monomers are prepared and characterized, with biotinylated formats and multimer assembly available for downstream multimer-based T cell detection and sorting workflows.
Analytical Characterization and Traceable QC
Reagent identity and quality are assessed through analytical characterization appropriate to the project, supporting comparability when screening multiple peptides or alleles across a program.
Multimer-Based Detection and Sorting Support
Where the study requires enumeration or recovery of antigen-specific T cells, multimer staining, flow cytometry readout, and multimer-positive sorting support can be included, with control setup, panel design, and gating discussed during project scoping.
How a Multimer T Cell Analysis Project Runs
Deliverables
| Item | Description |
|---|---|
| Peptide–MHC multimer reagents | Peptide-loaded or peptide-ready MHC reagents prepared in the requested format, including multimer-ready and fluorophore-conjugated options. |
| Peptide and allele documentation | Records of peptide sequence review, allele selection, and the chosen loading format agreed at project scoping. |
| Analytical characterization data | QC results for identity, purity, and multimer assembly appropriate to the requested format, delivered as a traceable data package. |
| T cell analysis readouts | Staining and detection results from multimer-based T cell analysis, reported with the gating and acquisition details used for the run. |
| Project summary report | A concise report covering the workflow performed, QC outcomes, and observations relevant to the stated study aim. |
Why Choose Our Peptide–MHC Multimer T Cell Analysis Services
Coordinated peptide-to-multimer workflow
Peptide supply, MHC monomer preparation, multimer assembly, and T cell analysis are handled within one accountable workflow, so teams do not need to coordinate separate peptide and protein vendors for a single study.
Class I and Class II project support
Projects can be configured around Class I or Class II alleles, with planning around allele pair selection, peptide presentation format, and the detection format best suited to the study aim.
Comparability across screening sets
When multiple peptides or alleles are screened, a consistent production strategy and traceable QC data support meaningful comparison across the set rather than one-off preparations.
Flexible loading strategies
Depending on scope, projects may use a placeholder peptide, an exchange workflow, or a staged loading strategy, with the approach confirmed during project design.
Further Reading
Research reference
1. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine. 2025. DOI: 10.1038/s41591-024-03418-4.
View articleStart Your Peptide–MHC Multimer T Cell Analysis Project
Share your target epitope, MHC allele, species, and the T cell readouts you need, and our team will scope a multimer analysis plan around your samples and timeline. We will confirm the peptide and allele strategy, multimer format, panel design, and reporting expectations before work begins so that deliverables match your downstream use.
Human donor studies can include PBMC isolation and immune cell preparation to align sample preparation with multimer analysis.